Yabut, Julian M.
Desjardins, Eric M.
Chan, Eric J.
Day, Emily A.
Leroux, Julie M.
Wang, Bo http://orcid.org/0000-0003-0604-1607
Crane, Elizabeth D.
Wong, Wesley http://orcid.org/0000-0003-3333-6689
Morrison, Katherine M. http://orcid.org/0000-0002-1737-256X
Crane, Justin D. http://orcid.org/0000-0002-5380-5676
Khan, Waliul I.
Steinberg, Gregory R. http://orcid.org/0000-0001-5425-8275
Article History
Received: 23 July 2019
Accepted: 16 December 2019
First Online: 23 January 2020
Competing interests
: J.M.Y., E.M.D., E.J.C., J.M.L., B.W., E.A.D., E.D.C., W.W., J.D.C., W.I.K. declare no competing interests. K.M.M. provides advisory services to Akcea Therapeutics Canada Inc. G.R.S. has received honoraria/consulting fees from Astra Zeneca, Boehringer, Eli-Lilly, Esperion Therapeutics, Novo Nordisk, Poxel, Pfizer, Merck, Rigel Therapeutics and Terns Therapeutics. G.R.S. has received research funding from Esperion Therapeutics. G.R.S. and W.I.K. hold a patent for inhibiting peripheral serotonin for the treatment of metabolic diseases including obesity.